

Effect of low to moderate dose corticosteroids on
and adults with influenza A(H1N1)pdm09 viral pneumon

Influenza and Other Respiratory Viruses

11, 345-354

DOI: 10.1111/irv.12456

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effect of low to moderate dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. <i>Influenza and Other Respiratory Viruses</i> , 2017, 11, 345-354.	1.5	117
2	Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009-2011. <i>Journal of Infectious Diseases</i> , 2018, 217, 1078-1088.	1.9	6
3	The role of adjuvant immunomodulatory agents for treatment of severe influenza. <i>Antiviral Research</i> , 2018, 150, 202-216.	1.9	82
4	Risk factors for nosocomial infection among hospitalised severe influenza A(H1N1)pdm09 patients. <i>Respiratory Medicine</i> , 2018, 134, 86-91.	1.3	29
5	Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 700-701.	2.5	66
6	Pandemic 2009 influenza A (H1N1)-associated deaths among children in China: A retrospective analysis. <i>Pediatric Investigation</i> , 2018, 2, 166-171.	0.6	4
7	Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. <i>PLoS Pathogens</i> , 2018, 14, e1007428.	2.1	61
8	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. <i>Intensive Care Medicine</i> , 2018, 44, 1470-1482.	3.9	123
9	The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. <i>Critical Care</i> , 2019, 23, 99.	2.5	297
10	Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases. <i>Internal Medicine</i> , 2019, 58, 3509-3519.	0.3	32
11	Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study. <i>BMC Infectious Diseases</i> , 2019, 19, 1080.	1.3	4
12	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. <i>Clinical Infectious Diseases</i> , 2019, 68, e1-e47.	2.9	449
13	Two Cases of Primary Human Parainfluenza Virus 1 Pneumonia in Which Bronchoalveolar Lavage Fluid Yielded Human Parainfluenza Virus 1. <i>Internal Medicine</i> , 2020, 59, 101-105.	0.3	5
14	Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. <i>Critical Care Medicine</i> , 2020, 48, e98-e106.	0.4	139
15	Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis. <i>Shock</i> , 2020, 54, 638-643.	1.0	57
16	Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: three case reports. <i>Journal of X-Ray Science and Technology</i> , 2020, 28, 885-892.	0.7	7
17	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	2.7	17
18	The unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?. <i>BMC Infectious Diseases</i> , 2020, 20, 862.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Risk factors for Coronavirus disease 2019 pneumonia after admission outside Wuhan, China. <i>Medicine (United States)</i> , 2020, 99, e22980.	0.4	0
20	Rheumatology Drugs and COVID-19. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 1-3.	0.4	0
21	One hundred years of (influenza) immunopathology. <i>Advances in Virus Research</i> , 2020, 107, 247-284.	0.9	3
22	Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2169-2183.	0.9	6
23	Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. <i>Scientific Reports</i> , 2020, 10, 13689.	1.6	29
24	Systemic Corticosteroids and Mortality in Severe and Critical COVID-19 Patients in Wuhan, China. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4230-e4239.	1.8	37
25	The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13412.	1.7	21
26	Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa421.	0.4	101
27	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <i>Shock</i> , 2020, 54, 416-437.	1.0	41
28	Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region. <i>PLoS ONE</i> , 2020, 15, e0238827.	1.1	32
29	Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 239.	0.8	15
30	Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. <i>Trials</i> , 2020, 21, 717.	0.7	35
31	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 569760.	2.2	30
32	Management of Osteoarthritis During the COVID-19 Pandemic. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 719-729.	2.3	17
33	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. <i>AAPS PharmSciTech</i> , 2020, 21, 130.	1.5	6
34	Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. <i>Cmaj</i> , 2020, 192, E756-E767.	0.9	166
35	Successful use of methylprednisolone for treating severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 325-327.	1.5	61
36	Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1632-1643.	0.6	10

#	ARTICLE	IF	CITATIONS
37	COVID-19 infection: the China and Italy perspectives. <i>Cell Death and Disease</i> , 2020, 11, 438.	2.7	76
38	Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. <i>Clinical Infectious Diseases</i> , 2020, 71, 740-747.	2.9	276
39	COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 737-762.	1.5	273
40	A 72-Year-Old Woman With Respiratory Failure and Bilateral Ground-Glass Opacities. <i>Chest</i> , 2020, 158, e41-e45.	0.4	1
41	Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 3044.	1.6	64
42	Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 18.	7.1	194
43	MiR-3150b-3p Inhibits the Progression of Colorectal Cancer Cells via Targeting GOLPH3. <i>Journal of Investigative Medicine</i> , 2020, 68, 425-429.	0.7	12
44	Current status of potential therapeutic candidates for the COVID-19 crisis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 59-73.	2.0	239
45	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020, 111, 102468.	3.0	103
46	Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. , 2020, 2, e0111.		87
47	Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?. <i>Critical Reviews in Microbiology</i> , 2020, 46, 182-193.	2.7	99
48	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 112-117.	2.8	33
49	Pacientes crÃ3nicos COVID-19 atendidos por anestesiÃ3logos en el Noroeste de EspaÃ3a: estudio multicÃ3ntrico, prospectivo, observacional. <i>Revista EspaÃ3ola De AnestesiologÃ3a Y ReanimaciÃ3n</i> , 2021, 68, 10-20.	0.1	15
50	Predictive value of cytokine/chemokine responses for the disease severity and management in children and adult cases with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2828-2837.	2.5	21
51	Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. <i>Chest</i> , 2021, 159, 1793-1802.	0.4	51
53	Clinical predictors of COVID-19 disease progression and death: Analysis of 214 hospitalised patients from Wuhan, China. <i>Clinical Respiratory Journal</i> , 2021, 15, 293-309.	0.6	17
54	MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 129-135.	2.0	37
55	Management of SARS-CoV-2 pneumonia. <i>Journal of Medical Virology</i> , 2021, 93, 1276-1287.	2.5	22

#	ARTICLE	IF	CITATIONS
56	Review of pharmacologic and immunologic agents in the management of COVID-19. <i>Biosafety and Health</i> , 2021, 3, 148-155.	1.2	7
57	Critically ill COVID-19 patients attended by anesthesiologists in northwestern Spain: A multicenter prospective observational study. <i>Revista Española De Anestesiología Y Reanimación (English Edition)</i> , 2021, 68, 10-20.	0.1	1
58	Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 231-247.	1.3	22
59	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. <i>Viruses</i> , 2021, 13, 161.	1.5	17
60	Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. <i>Clinical Rheumatology</i> , 2021, 40, 3227-3237.	1.0	29
61	Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 564943.	1.2	0
62	Two Cases of Primary Rhinovirus Pneumonia with Multiple Pulmonary Nodules. <i>Internal Medicine</i> , 2021, 60, 435-439.	0.3	2
63	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	1.0	18
64	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021, 30, 200346.	3.0	24
65	Characteristics of viral pneumonia in the COVID-19 era: an update. <i>Infection</i> , 2021, 49, 607-616.	2.3	39
66	Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	1.4	15
67	Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19: Experience and Lessons from the SARS Epidemic. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 983-995.	2.0	43
68	Factors associated with delayed viral shedding in COVID-19 infected patients: A retrospective small-scale study. <i>Respiratory Medicine</i> , 2021, 178, 106328.	1.3	8
69	Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before-After Study (CortiCOVID Study). <i>Open Respiratory Archives</i> , 2021, 3, 100086.	0.0	3
70	Impact of corticosteroids in hospitalised COVID-19 patients. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000766.	1.2	27
71	The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. <i>Frontiers in Pharmacology</i> , 2021, 12, 633292.	1.6	10
72	Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1553-1562.	2.0	12
73	Use of traditional Chinese medicine as an adjunctive treatment for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e26641.	0.4	8

#	ARTICLE	IF	CITATIONS
74	Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia. Infection and Drug Resistance, 2021, Volume 14, 2667-2674.	1.1	2
75	Targeting the Host Response: Can We Manipulate Extracellular Matrix Metalloproteinase Activity to Improve Influenza Virus Infection Outcomes?. Frontiers in Molecular Biosciences, 2021, 8, 703456.	1.6	0
77	Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study. BMC Infectious Diseases, 2021, 21, 805.	1.3	4
78	Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. World Journal of Critical Care Medicine, 2021, 10, 244-259.	0.8	2
79	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
80	Corticosteroids as adjunctive therapy in the treatment of influenza. The Cochrane Library, 2019, 2, CD010406.	1.5	114
81	Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clinical Rheumatology, 2020, 39, 2031-2037.	1.0	9
82	On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, The, 2020, 395, 683-684.	6.3	495
86	Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs. Journal of Immunology Research, 2020, 2020, 1-21.	0.9	6
87	Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases. World Journal of Clinical Cases, 2020, 8, 5952-5961.	0.3	13
88	Progress and current status of influenza researches in China. Journal of Translational Internal Medicine, 2019, 7, 53-58.	1.0	4
89	The application of corticosteroids in COVID-19: A two-edged sword. Journal of Translational Internal Medicine, 2020, 8, 66-70.	1.0	5
90	COVID-19 in China: From epidemiology to treatment (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	4
91	MicroRNA-4485 ameliorates severe influenza pneumonia via inhibition of the STAT3/PI3K/AKT signaling pathway. Oncology Letters, 2020, 20, 1-1.	0.8	13
92	A literature review of drugs for the treatment of COVID-19. Caribbean Medical Journal, 0, , .	0.1	0
93	COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome. Revista Espanola De Quimioterapia, 2021, 34, 33-43.	0.5	8
94	Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases. World Journal of Clinical Cases, 2020, 8, 5949-5958.	0.3	0
95	A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	0

#	ARTICLE	IF	CITATIONS
96	The use of corticosteroids for COVID-19 infection. African Journal of Thoracic and Critical Care Medicine, 2020, 26, .	0.3	0
98	Sirolimus combined with oseltamivir and corticosteroid treatment for a puerpera with severe pneumonia caused by 2009 pandemic H1N1: A case report. Biosafety and Health, 2021, , .	1.2	0
99	Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110639.	1.0	12
100	The use of corticosteroids for COVID-19 infection. African Journal of Thoracic and Critical Care Medicine, 2020, 26, 87.	0.3	1
101	Efficacité et innocuité des corticostéroïdes dans le traitement de la COVID-19 selon des données pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitalière et le syndrome de détresse respiratoire aiguë : revue systématique et méta-analyse. Cmaj, 2020, 192, E1571-E1584.	0.9	1
102	« <i>Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale.</i> Journal of Clinical Medicine Research, 2022, 14, 53-79.	0.6	4
103	Osteoarthritis, Corticosteroids and Role of CYP Genes in COVID-19 Patients: A Mini Review. Journal of Pure and Applied Microbiology, 2022, 16, 18-25.	0.3	1
105	A Review Article on the Therapeutic Potential of Medicinal Plants for Prevention and Treatment of secondary infection in patients with COVID-19. Current Traditional Medicine, 2021, 08, .	0.1	0
106	Effects of Antiviral Therapy and Glucocorticoid Therapy on Fever Duration in Pediatric Patients with Influenza. Medicina (Lithuania), 2021, 57, 1385.	0.8	2
107	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. World Journal of Critical Care Medicine, 2022, 11, 269-297.	0.8	2
108	Association between Glucocorticoids and Mortality in Patients with Severe Pneumonia: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-10.	0.7	3
109	The The use of corticosteroid therapy for COVID-19 patients: an evidence-based overview. Revista Ciencias Em Saude, 2022, 12, 4-11.	0.0	0
110	Comparative analysis of elderly hospitalized patients with coronavirus disease 2019 or influenza A H1N1 virus infections. International Journal of Infectious Diseases, 2022, , .	1.5	0
111	Analysis of risk factors of fungal superinfections in viral pneumonia patients: A systematic review and meta-analysis. Immunity, Inflammation and Disease, 2023, 11, .	1.3	1
112	Outcomes of corticosteroid treatment in critical ill adult patients with respiratory viruses-related community acquired pneumonia : a propensity-matched case control study. Journal of Microbiology, Immunology and Infection, 2023, , .	1.5	0
113	Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia. Journal of International Medical Research, 2023, 51, 030006052211492.	0.4	0